IP Library Granted Patent US 10,953,018
Granted Patent B2
US 10,953,018 · App. 16/669,262 · Granted Mar 23, 2021

Emulsion formulations of aprepitant

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,953,018
App. No.
16/669,262
Granted
Mar 23, 2021
Kind
B2
Abstract

Disclosed herein are novel pharmaceutical formulations of aprepitant suitable for parenteral administration including intravenous administration. Also included are formulations including both aprepitant and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Claims (24)

1. A method for treating nausea and vomiting in a subject in need thereof comprising administering to the subject a physically stable pharmaceutical composition, comprising:

aprepitant;

an emulsifier;

an oil; and

water;

wherein the ratio of the emulsifier to aprepitant (wt %:wt %) ranges from about 18:1 to 22:1, wherein the ratio of the oil to aprepitant (wt %:wt %) ranges from about 11:1 to 15:1, and

wherein the composition is an emulsion.

2. The method according to claim 1 , wherein the nausea and vomiting is chemotherapy induced nausea and vomiting.

3. The method according to claim 2 , wherein the chemotherapy induced nausea and vomiting is in response to highly emetic chemotherapy.

4. The method according to claim 2 , wherein the chemotherapy induced nausea and vomiting is in response to moderately emetic chemotherapy.

5. The method according to claim 1 , wherein the administering is intravenous.

6. The method according to claim 1 , wherein the composition comprises 0.4 wt/wt % to 1.0 wt/wt % aprepitant.

7. The method according to claim 1 , wherein the composition comprises 0.7 wt/wt % aprepitant.

8. The method according to claim 1 , wherein the composition comprises 11 wt/wt % to 15 wt/wt % emulsifier.

9. The method according to claim 1 , wherein the composition comprises 14 wt/wt % emulsifier.

10. The method according to claim 1 , wherein the emulsifier is egg yolk lecithin.

11. The method according to claim 1 , wherein the composition comprises 9 wt/wt % to 10 wt/wt % oil.

12. The method according to claim 1 , wherein the oil is soybean oil.

13. The method according to claim 1 , wherein the composition further comprises sodium oleate as a pH modifier.

14. The method according to claim 1 , wherein the pH of the composition ranges from 7.5 to 9.0.

15. The method according to claim 1 , wherein the composition further comprises 3 wt/wt % to 8 wt/wt % sucrose.

16. The method according to claim 1 , wherein the composition further comprises 5 wt/wt % sucrose.

17. The method according to claim 1 , wherein the composition further comprises 2 wt/wt % to 6 wt/wt % ethanol.

18. The method according to claim 1 , wherein the composition further comprises less than 6 wt/wt % ethanol.

Assignments (2)
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Aug 9, 2023
From: HERON THERAPEUTICS, INC.
To: HERCULES CAPITAL, INC., AS AGENT
Reel/Frame 064546/0453 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 30, 2019
From: OTTOBONI, THOMAS B.; HAN, HAN
To: HERON THERAPEUTICS, INC.
Reel/Frame 050870/0046 →